NEW YORK (GenomeWeb News) – Affymetrix today announced a deal with Massachusetts General Hospital to co-develop cancer biomarker tests using Affy's QuantiGene ViewRNA Assay platform.

As part of the deal, Affy has the commercialization rights to new tests resulting from the collaboration. Other terms were not disclosed.

The QuantiGene ViewRNA Assay is an in situ hybridization assay with single-transcript in single-cell detection capability. The platform is for research-use only.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.